Bone Metastases of Diverse Primary Origin Frequently Express the VDR (Vitamin D Receptor) and CYP24A1

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Nov 11

PMID 36362766

Authors

Jonas Seiler

Regina Ebert

Maximilian Rudert

Marietta Herrmann

Ellen Leich

Manuela Weissenberger

Konstantin Horas

Affiliations

Soon will be listed here.

Abstract

Active vitamin D (1,25(OH)2D3) is known to exert direct anti-cancer actions on various malignant tissues through binding to the vitamin D receptor (VDR). These effects have been demonstrated in breast, prostate, renal and thyroid cancers, which all have a high propensity to metastasise to bone. In addition, there is evidence that vitamin D catabolism via 24-hydroxylase (CYP24A1) is altered in tumour cells, thus, reducing local active vitamin D levels in cancer cells. The aim of this study was to assess VDR and CYP24A1 expression in various types of bone metastases by using immunohistochemistry. Overall, a high total VDR protein expression was detected in 59% of cases (39/66). There was a non-significant trend of high-grade tumours towards the low nuclear VDR expression ( = 0.07). Notably, patients with further distant metastases had a reduced nuclear VDR expression ( = 0.03). Furthermore, a high CYP24A1 expression was detected in 59% (39/66) of bone metastases. There was a significant positive correlation between nuclear VDR and CYP24A1 expression ( = 0.001). Collectively, the VDR and CYP24A1 were widely expressed in a multitude of bone metastases, pointing to a potential role of vitamin D signalling in cancer progression. This is of high clinical relevance, as vitamin D deficiency is frequent in patients with bone metastases.

References

Hofbauer L, Rachner T, Coleman R, Jakob F . Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol. 2014; 2(6):500-12. DOI: 10.1016/S2213-8587(13)70203-1. View

Yong M, Jensen A, Jacobsen J, Norgaard M, Fryzek J, Sorensen H . Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011; 129(2):495-503. DOI: 10.1007/s10549-011-1475-5. View

Srinivasan M, Parwani A, Hershberger P, Lenzner D, Weissfeld J . Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol. 2010; 123(1-2):30-6. PMC: 3010457. DOI: 10.1016/j.jsbmb.2010.10.002. View

Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese L . Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010; 10:483. PMC: 2945944. DOI: 10.1186/1471-2407-10-483. View

Feldman D, Krishnan A, Swami S, Giovannucci E, Feldman B . The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14(5):342-57. DOI: 10.1038/nrc3691. View

Zhang Y, Guo Q, Zhang Z, Bai N, Liu Z, Xiong M . VDR status arbitrates the prometastatic effects of tumor-associated macrophages. Mol Cancer Res. 2014; 12(8):1181-91. DOI: 10.1158/1541-7786.MCR-14-0036. View

Campolina-Silva G, Maria B, Mahecha G, Oliveira C . Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging-related prostate lesions. Prostate. 2018; 78(7):532-546. DOI: 10.1002/pros.23498. View

Parise R, Egorin M, Kanterewicz B, Taimi M, Petkovich M, Lew A . CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer. 2006; 119(8):1819-28. DOI: 10.1002/ijc.22058. View

Chen G, Kim S, King A, Zhao L, Simpson R, Christensen P . CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res. 2010; 17(4):817-26. PMC: 3058389. DOI: 10.1158/1078-0432.CCR-10-1789. View

10.

Ooi L, Zhou H, Kalak R, Zheng Y, Conigrave A, Seibel M . Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 2010; 70(5):1835-44. DOI: 10.1158/0008-5472.CAN-09-3194. View

11.

Muindi J, Yu W, Ma Y, Engler K, Kong R, Trump D . CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 2010; 151(9):4301-12. PMC: 2940491. DOI: 10.1210/en.2009-1156. View

12.

Podgorska E, Kim T, Janjetovic Z, Urbanska K, Tuckey R, Bae S . Knocking out the Vitamin D Receptor Enhances Malignancy and Decreases Responsiveness to Vitamin D3 Hydroxyderivatives in Human Melanoma Cells. Cancers (Basel). 2021; 13(13). PMC: 8269360. DOI: 10.3390/cancers13133111. View

13.

Wang K, Dong M, Sheng W, Liu Q, Yu D, Dong Q . Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer. Histopathology. 2015; 67(3):386-97. DOI: 10.1111/his.12663. View

14.

Kim Y, Je Y . Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014; 110(11):2772-84. PMC: 4037823. DOI: 10.1038/bjc.2014.175. View

15.

Osanai M, Lee G . CYP24A1-induced vitamin D insufficiency promotes breast cancer growth. Oncol Rep. 2016; 36(5):2755-2762. DOI: 10.3892/or.2016.5072. View

16.

Spina C, Tangpricha V, Uskokovic M, Adorinic L, Maehr H, Holick M . Vitamin D and cancer. Anticancer Res. 2006; 26(4A):2515-24. View

17.

Wang Y, Zhu J, Deluca H . Where is the vitamin D receptor?. Arch Biochem Biophys. 2012; 523(1):123-33. DOI: 10.1016/j.abb.2012.04.001. View

18.

Trivedi T, Zheng Y, Fournier P, Murthy S, John S, Schillo S . The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget. 2017; 8(16):26687-26701. PMC: 5432290. DOI: 10.18632/oncotarget.15803. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Coleman R, Croucher P, Padhani A, Clezardin P, Chow E, Fallon M . Bone metastases. Nat Rev Dis Primers. 2020; 6(1):83. DOI: 10.1038/s41572-020-00216-3. View